Literature DB >> 9638817

The use of transgenic mice in the investigation of transmissible spongiform encephalopathies.

C Weissmann1, M Fischer, A Raeber, H Büeler, A Sailer, D Shmerling, T Rülicke, S Brandner, A Aguzzi.   

Abstract

The prion, the transmissible agent that causes spongiform encephalopathies such as scrapie, bovine spongiform encephalopathy and Creutzfeldt-Jakob disease, is believed to be devoid of nucleic acid and to be identical to PrPSc (prion protein: scrapie form), a modified form of the normal host protein PrPC (prion protein: cellular form) which is encoded by the single copy gene Prnp. The 'protein only' hypothesis proposes that PrPSc, when introduced into a normal host, causes the conversion of PrPC into PrPSc; it therefore predicts that an animal devoid of PrPC should be resistant to prion diseases. The authors generated homozygous Prnp(o/o) ('PrP knockout') mice and showed that, after inoculation with prions, these mice remained free from scrapie for at least two years while wild-type controls all died within six months. There was no propagation of prions in the Prnp(o/o) animals. Surprisingly, heterozygous Prnp(o/+) mice, which express PrPC at about half the normal level, also showed enhanced resistance to scrapie despite high levels of infectious agent and PrPSc in the brain at an early stage. After introduction of murine PrP transgenes, Prnp(o/o) mice became highly susceptible to mouse--but not to hamster--prions, while the insertion of Syrian hamster PrP transgenes rendered the mice susceptible to hamster prions but much less susceptible to mouse prions. These complementation experiments enabled the application of reverse genetics. The authors prepared animals transgenic for genes encoding PrP with amino terminal deletions of various lengths and found that PrP that lacks 48 amino proximal amino acids (which comprise four of the five octa repeats of PrP) is still biologically active.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9638817     DOI: 10.20506/rst.17.1.1079

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  7 in total

Review 1.  Transgenesis applied to transmissible spongiform encephalopathies.

Authors:  Jean-Luc Vilotte; Hubert Laude
Journal:  Transgenic Res       Date:  2002-12       Impact factor: 2.788

2.  Disease-associated prion protein elicits immunoglobulin M responses in vivo.

Authors:  Mourad Tayebi; Perry Enever; Zahid Sattar; John Collinge; Simon Hawke
Journal:  Mol Med       Date:  2004 Jul-Dec       Impact factor: 6.354

3.  Functions of the cellular prion protein, the end of Moore's law, and Ockham's razor theory.

Authors:  José A del Río; Rosalina Gavín
Journal:  Prion       Date:  2016       Impact factor: 3.931

Review 4.  Prion disease: experimental models and reality.

Authors:  Sebastian Brandner; Zane Jaunmuktane
Journal:  Acta Neuropathol       Date:  2017-01-13       Impact factor: 17.088

5.  Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity.

Authors:  Despoina Goniotaki; Asvin K K Lakkaraju; Amulya N Shrivastava; Pamela Bakirci; Silvia Sorce; Assunta Senatore; Rajlakshmi Marpakwar; Simone Hornemann; Fabrizio Gasparini; Antoine Triller; Adriano Aguzzi
Journal:  PLoS Pathog       Date:  2017-11-27       Impact factor: 6.823

6.  The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration.

Authors:  Danica Chen; Andrew D Steele; Gregor Hutter; Joanne Bruno; Arvind Govindarajan; Erin Easlon; Su-Ju Lin; Adriano Aguzzi; Susan Lindquist; Leonard Guarente
Journal:  Exp Gerontol       Date:  2008-08-30       Impact factor: 4.032

7.  Preclinical detection of variant CJD and BSE prions in blood.

Authors:  Caroline Lacroux; Emmanuel Comoy; Mohammed Moudjou; Armand Perret-Liaudet; Séverine Lugan; Claire Litaise; Hugh Simmons; Christelle Jas-Duval; Isabelle Lantier; Vincent Béringue; Martin Groschup; Guillaume Fichet; Pierrette Costes; Nathalie Streichenberger; Frederic Lantier; Jean Philippe Deslys; Didier Vilette; Olivier Andréoletti
Journal:  PLoS Pathog       Date:  2014-06-12       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.